Kathy Steece-Collier, Ph.D.
Professor of Translational Science & Molecular Medicine
Teaching Faculty, MSU Neuroscience Program
Mailing Address & Contact Information
Translational Science & Molecular Medicine
Michigan State University
College of Human Medicine
333 Bostwick Ave. NE
Grand Rapids, MI 49503
|Institution||Field of Study||Degree Earned||Year|
|Eureka College, Eureka, IL||Chemistry||B.S.||1981|
|Eureka College, Eureka, IL||Biology||B.S.||1981|
|University of Illinois School of Medicine, Chicago, IL||Physiology||Ph.D.||1986|
|University of Rochester School of Medicine, Rochester, NY||Neuroanatomy||Postdoctoral Fellow||1986-1990|
Kathy Steece-Collier, Ph.D. is Professor of Translational Science and Molecular Medicine at Michigan State University. She is a member of the National Institutes of Health Clinical Neuroplasticity and Neurotransmitters (CNNT) Study Section, serves as grant reviewer and progress assessor for the Michael J. Fox Foundation for Parkinson’s research, and is Past-President of the American Society for Neural Therapy and Repair (ASNTR).
Dr. Steece-Collier received a dual BS with high honors from Eureka College in Biology and Chemistry, and a Ph.D. from the University of Illinois Medical Center in Chicago. She did a postdoctoral research fellowship under the tutelage of Dr. John R. Sladek, Jr. at the University of Rochester. She has held faculty appointments at Rosalind Franklin University/the Chicago Medical School, Rush University in Chicago, the University of Cincinnati, and joined Michigan State University in 2010.
We study primarily animal models of DA terminal replacement including 1) grafting new dopamine neurons, and 2) trophic factor induced sprouting of remaining DA neurons. Both approaches have been used with intermittent success in clinical trials for PD, and are aimed at restoring lost DA innervation in the target brain region to which nigral DA neurons project; i.e.. the striatum. We also study the relationship of striatal pathology to the development of levodopa-induced dyskinesias in rodent models of PD.
The goal of our research is to understand why experimental therapies aimed at replacing DA terminals in the PD brain have given largely disappointing results in clinical trials in individuals with PD, and how we can more consistently and effectively remodel the circuitry of the parkinsonian brain to improve therapeutic outcome of such therapies and prevent dyskinetic side-effects of standard pharmacotherapy.
Honors, Recognitions, and Service
- American Society for Neural Therapy and Repair (Charter Member, Secretary [2007-2009], Treasurer [2002-2004], Program Chair [2005-2006], President [2009-2010])
- NIH CNNT study section (2009- 2013 regular member; 2007- 2009 ad hoc)
- M J Fox Foundation, grant reviewer and progress assessor (2003-present)
- The Bernard Sanberg Memorial Award For Brain Repair, May 2006
- PhD Thesis Opponent, Umea University, Umea Sweden, May 2008
- Schweppe Foundation Career Development Award, 1997-2000
- Board of Trustees Award for Outstanding Research, Finch University of the Health Sciences/ The Chicago Medical School, 1998
- Outstanding Young Alum, Eureka College, 1995
- Behavioral assessment of animal models of Parkinson’s disease
- Stereotaxic brain surgery
- Electron microscopy
- Neuron reconstruction
- Golgi impregnation
- Dendritic spine quantification
- Confocal microscopy
- Brain microdissection